PARP inhibitors are emerging as an important therapeutic class of drugs for the treatment of various cancers like ovarian cancer, breast cancer, and prostate cancer. PARP inhibitors act by inhibiting the DNA repair enzyme called Poly (ADP-ribose) polymerase. The inhibition of PARP enzyme prevents cancer cells from repairing DNA damage caused by chemotherapy or radiation therapy. This leads to cell death in cancer cells. PARP inhibitors are increasingly being used as a maintenance therapy for ovarian cancer and as a first-line therapy for metastatic breast cancer with BRCA1/2 mutations.
The global PARP Inhibitor Market is estimated to be valued at US$ 6.13 Bn in 2023 and is expected to exhibit a CAGR of 6.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The rising adoption of PARP inhibitors across various chemotherapy settings is one of the key drivers of the PARP inhibitor market growth. According to recent clinical studies, PARP inhibitors have demonstrated survival benefits when used as maintenance treatment in platinum-sensitive relapsed ovarian cancer and as monotherapy in metastatic breast and prostate cancers associated with BRCA1/2 mutations. Several pharmaceutical companies are continuously investing in R&D activities to develop novel PARP inhibitor drugs and expand the approved treatment lines. This rising focus on developing new treatment opportunities with PARP inhibitors is expected to propel the market growth over the forecast period.
Segment Analysis
The global PARP inhibitor market is segmented based on drug class, application, route of administration, and end-use. The olapirib segment dominates the drug class segment owing to its strong efficacy and selective inhibition of PARP1 and PARP2 enzymes.
Key Takeaways
Global PARP Inhibitor Market Trends are expected to witness high growth over the forecast period of 2023 to 2030.
Regional analysis:North America is expected to hold the largest share of the global PARP inhibitor market during the forecast period. This is attributed to the increasing prevalence of breast and ovarian cancer, rising demand for targeted therapies like PARP inhibitors, and well-established healthcare infrastructure.
Key players operating in the PARP inhibitor market are FLSmidth & Co. A/S, Metso Oyj, Koppern Group, CITIC Heavy Industries Co. Ltd. (CITIC HIC), ThyssenKrupp Industrial Solutions AG (Polysius AG), SGS S.A., KHD Humboldt Wedag International AG, Outotec Oyj, and ABB Ltd. These players are focusing on new product launches, partnerships, mergers & acquisitions and expansions to increase their market share in the PARP inhibitor market.
Get More Insights on this Topic- https://www.dailyprbulletin.com/parp-inhibitor-market-future-trends-and-value-insights/
The Global PARP Inhibitor Biomarkers market held USD 465.6 million in 2020 and is to grow with a CAGR of 24.2% from 2020-2030.
It consists of a group of 17 enzymes combining several (poly) ADP-ribose units in a chain and transferring them into the target proteins.
It is believed that PARP inhibitors are trapped in single-strand DNA pauses that lead to dual-strand DNA pausing when replication of the DNA is attempted.
Double-stranded DNA breaks would normally be re-mediated by the HRR process, an advanced process that includes several proteins, particularly BRCA1 and BRCA2, which are also known as PARP inhibitors biomarkersMarket Dynamics and Factors:Download Research Sample with Industry Insights @ https://www.trendsmarketresearch.com/report/sample/13663The main drivers for PARP inhibitors biomarkers market growth are the increasing prevalence of cancer worldwide.
In total, around 1 in 6 deaths occur because of ca, according to the same source.Increasing breast and ovarian cancer incidences are also expected to lead to PARP inhibitors biomarkers market growth over the projected period.
Breast cancer was among the 2nd largest total number of cancer cases worldwide, for example according to a 2018 report by the World Cancer Research Fund, which in 2018 accounted for 2,088,849 new cases.
